Future growth expectations in sales/revenue/volumes?

The company targets a revenue growth CAGR of 18% to 20% over the next 3 to 5 years. They expect exports to increase to about 60% of total sales, with domestic sales around 40%. Capacity expansion of around INR 250-270 crores over 2-3 years aims to add approximately INR 1,000 crores in revenue. Current capacity utilization is about 90% for technicals and 55% for formulations, expected to rise with new registrations. New product launches include 4-5 products planned for FY23 and similar numbers for FY24, focusing on herbicides, fungicides, and insecticides. The product pipeline aims for $600-$70

Any current/future new fundraising through debt or equity?

There is no specific mention of any planned fundraising through debt or equity in the current or future period. The company plans to fund its CAPEX of around ₹250 crore over the next two to three years mostly through internal accruals. They have good internal accruals currently and expect to use surplus cash generated for investments, registrations, new geographies, and new products. Management is open to inorganic acquisitions if good synergistic opportunities arise, supported by strong capital accruals. No explicit intention to raise external debt or equity was indicated during the discussio

Any current/future capex/capital investment/strategic investment?

Heranba Industries plans CAPEX of around ₹250-270 crores over the next 2-3 years, mainly funded through internal accruals. Approximately 70% of this CAPEX is directed toward capacity expansion for new products, with the remaining 30% for existing products. New technical capacity addition expected in phases, potentially adding 5,000 to 10,000 metric tons. A new technical manufacturing site is planned to start operations by Q3 (September-October). The company aims to leverage surplus cash generated (estimated ₹600-650 crores operating cash flow over FY22-FY24) for new investments including regis

Future growth expectations in earnings/operating earnings/profits/EPS?

The company expects revenue growth at a CAGR of 18% to 20% over the next 3 to 5 years. EBITDA margins are expected to be maintained around 18% to 19%, with potential for improvement due to new product launches. Gross margins are anticipated to be stable around 35% to 36% on a full-year basis. Earnings per share (EPS) showed a strong 61.75% increase y-o-y recently, indicating robust profit growth. Operating profits increased significantly in FY21 and are expected to sustain with new registrations and geographical expansion. New product launches, especially in technicals and formulations, as wel

IN US

Sale is live|00:00:00left today

Heranba Industries LtdQ2 FY21Fertilizers & Agrochemicals

Heranba Industries Ltd Q2 FY21 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹187Market Cap: ₹818 CrSector: Fertilizers & Agrochemicals

Management growth scorecard

Revenue

Category 3

Margin

Category 3

Fundraise

N/A

Order

N/A

Capex

Yes

1 of 3 growth signals are positive — mixed outlook.

Full analysis

Revenue guidance

Category 3

→The company targets a revenue growth CAGR of 18% to 20% over the next 3 to 5 years.
→They expect exports to increase to about 60% of total sales, with domestic sales around 40%.
→Capacity expansion of around INR 250-270 crores over 2-3 years aims to add approximately INR 1,000 crores in revenue.
→Current capacity utilization is about 90% for technicals and 55% for formulations, expected to rise with new registrations.
→New product launches include 4-5 products planned for FY23 and similar numbers for FY24, focusing on herbicides, fungicides, and insecticides.
→The product pipeline aims for $600-$700 million opportunity size in US, Europe, and LATAM markets.
→Management targets sustaining or improving EBITDA margins around 18-19%.
→Growth driven by both volume and value increases, supported by internal accruals and potential inorganic opportunities.

Margin guidance

Category 3

→The company expects revenue growth at a CAGR of 18% to 20% over the next 3 to 5 years.
→EBITDA margins are expected to be maintained around 18% to 19%, with potential for improvement due to new product launches.
→Gross margins are anticipated to be stable around 35% to 36% on a full-year basis.
→Earnings per share (EPS) showed a strong 61.75% increase y-o-y recently, indicating robust profit growth.
→Operating profits increased significantly in FY21 and are expected to sustain with new registrations and geographical expansion.
→New product launches, especially in technicals and formulations, as well as expansion in exports to US, Europe, and LATAM, will drive growth.
→Capital expenditure of about ₹250-270 crores over 2-3 years aims at capacity expansion and new product development, funded mainly through internal accruals.
→Management remains open to inorganic growth opportunities to utilize surplus cash post-capex.

3 more insights locked — sign up free to unlock

Fundraise plans

→There is no specific mention of any planned fundraising through debt or equity in the current or future period.
→The company plans to fund its CAPEX of around ₹250 crore over the next two to three years mostly through internal accruals.
→They have good internal accruals currently and expect to use surplus cash generated for investments, registrations, new geographies, and new products.
→Management is open to inorganic acquisitions if good synergistic opportunities arise, supported by strong capital accruals.
→No explicit intention to raise external debt or equity was indicated during the discussion.

Order book

- The transcript does not provide explicit details on the current or expected order book or specific pending orders in terms of volume or value. - It is mentioned that demand is strong, but exports are slightly delayed due to logistical challenges like container scarcity, causing slower movement rather than lost demand. - The company has orders in place for both domestic and export markets, with domestic growth noted as strong (90% growth) and export orders pending but with slow dispatch due to logistics. - The company has ongoing registrations and product launches planned, indicating a healthy future demand pipeline. - New product launches and capacity expansions suggest expectations for increasing order inflow in the coming years. Therefore, while no precise order book figures are provided, the company indicates a robust demand environment with some export shipment delays affecting order fulfillment timing.

Capex plans

Yes

→Heranba Industries plans CAPEX of around ₹250-270 crores over the next 2-3 years, mainly funded through internal accruals.
→Approximately 70% of this CAPEX is directed toward capacity expansion for new products, with the remaining 30% for existing products.
→New technical capacity addition expected in phases, potentially adding 5,000 to 10,000 metric tons.
→A new technical manufacturing site is planned to start operations by Q3 (September-October).
→The company aims to leverage surplus cash generated (estimated ₹600-650 crores operating cash flow over FY22-FY24) for new investments including registrations, new geographies, and product launches.
→Management is open to inorganic growth and acquisitions if synergistic opportunities arise.
→R&D plans include 4-5 new products launches each in FY23 and FY24, with additional pipeline development ongoing.

How does Heranba Industries Ltd rank vs peers in Fertilizers & Agrochemicals?

Pro feature

1Heranba Industries Ltd

Rev 3Mar 3

See full Fertilizers & Agrochemicals sector rankings

Want more stocks like Heranba Industries Ltd?

Build an AI portfolio filtered by sector, market cap, and growth rank. Takes 2 minutes.

Build my portfolio